# Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA)

> **NCT04959799** · — · COMPLETED · sponsor: **Aziende Chimiche Riunite Angelini Francesco S.p.A** · enrollment: 98 (actual)

## Conditions studied

- Diabetes
- Infection

## Interventions

- **DRUG:** Dalbavancin

## Key facts

- **NCT ID:** NCT04959799
- **Lead sponsor:** Aziende Chimiche Riunite Angelini Francesco S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-02
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2022-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04959799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04959799, "Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04959799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*